Carotid Doppler ultrasonographic findings of dapagliflozin use in type 2 diabetic patients.

IF 2.7 4区医学 Q3 ENDOCRINOLOGY & METABOLISM Aging Male Pub Date : 2020-12-01 Epub Date: 2020-04-28 DOI:10.1080/13685538.2020.1758657

Attila Onmez, Feyzi Gokosmanoglu, Gulsah Baycelebi, Ali Ahmet Arıkan

{"title":"Carotid Doppler ultrasonographic findings of dapagliflozin use in type 2 diabetic patients.","authors":"Attila Onmez, Feyzi Gokosmanoglu, Gulsah Baycelebi, Ali Ahmet Arıkan","doi":"10.1080/13685538.2020.1758657","DOIUrl":null,"url":null,"abstract":"Aim: Sodium-glucose cotransporter 2 inhibitors have been shown to reduce the risk of cardiovascular disease in type 2 diabetes (T2DM) patients. The purpose of this study was to evaluate cardiovascular disease risk indirectly through Doppler ultrasonography (USG) of carotid artery vascular markers in T2DM patients using dapagliflozin.Methods: One hundred forty-five patients presenting to our clinic between March 2016 and June 2018 and diagnosed with T2DM were included in the study. These were divided into two groups - a dapagliflozin group of 85 patients and a 60-member non-dapagliflozin control group. Common carotid artery end-diastolic velocity (EDV), peak systolic velocity (PSV), and resistive index (RI) parameters were evaluated using Doppler USG in both groups.Results: The mean duration of follow-up was 2.2 ± 0.4 years. Mean ages were 45 ± 14 years in the dapagliflozin group and 42 ± 15 in the control group. Mean HbA1c was 7.4 ± 1.6 in the dapagliflozin group and 7.3 ± 2.1 in the control group. Common carotid artery, PSV, and EDV parameters were higher (p = .012/p = .036), while RI was lower (p ˂ .001), in the dapagliflozin group than in the control group.Conclusion: Vascular resistance was lower in the group using dapagliflozin for diabetes management.","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":"23 5","pages":"1246-1250"},"PeriodicalIF":2.7000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/13685538.2020.1758657","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2020.1758657","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/4/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: Sodium-glucose cotransporter 2 inhibitors have been shown to reduce the risk of cardiovascular disease in type 2 diabetes (T2DM) patients. The purpose of this study was to evaluate cardiovascular disease risk indirectly through Doppler ultrasonography (USG) of carotid artery vascular markers in T2DM patients using dapagliflozin.

Methods: One hundred forty-five patients presenting to our clinic between March 2016 and June 2018 and diagnosed with T2DM were included in the study. These were divided into two groups - a dapagliflozin group of 85 patients and a 60-member non-dapagliflozin control group. Common carotid artery end-diastolic velocity (EDV), peak systolic velocity (PSV), and resistive index (RI) parameters were evaluated using Doppler USG in both groups.

Results: The mean duration of follow-up was 2.2 ± 0.4 years. Mean ages were 45 ± 14 years in the dapagliflozin group and 42 ± 15 in the control group. Mean HbA1c was 7.4 ± 1.6 in the dapagliflozin group and 7.3 ± 2.1 in the control group. Common carotid artery, PSV, and EDV parameters were higher (p = .012/p = .036), while RI was lower (p ˂ .001), in the dapagliflozin group than in the control group.

Conclusion: Vascular resistance was lower in the group using dapagliflozin for diabetes management.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

达格列净用于2型糖尿病患者的颈动脉多普勒超声表现。

目的:钠-葡萄糖共转运蛋白2抑制剂已被证明可降低2型糖尿病(T2DM)患者心血管疾病的风险。本研究的目的是通过多普勒超声(USG)对使用达格列净的T2DM患者颈动脉血管标志物进行间接评价心血管疾病的风险。方法:研究纳入了2016年3月至2018年6月期间就诊并诊断为T2DM的145例患者。这些患者被分为两组——85名达格列净患者和60名非达格列净对照组。应用多普勒USG评价两组患者颈总动脉舒张末期速度(EDV)、收缩峰值速度(PSV)和阻力指数(RI)参数。结果:平均随访时间为2.2±0.4年。达格列净组平均年龄为45±14岁，对照组平均年龄为42±15岁。达格列净组平均HbA1c为7.4±1.6，对照组为7.3±2.1。dapagliflozin组颈总动脉、PSV和EDV参数高于对照组(p = 0.012 /p = 0.036)， RI低于对照组(p小于0.001)。结论:应用达格列净治疗糖尿病组血管阻力较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Aging Male 医学-泌尿学与肾脏学

CiteScore

6.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year. The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to: Diagnosis and treatment of late-onset hypogonadism Metabolic syndrome and related conditions Treatment of erectile dysfunction and related disorders Prostate cancer and benign prostate hyperplasia.